Australia funds age-related medical R&D:
This article was originally published in Clinica
Australia has given Aus$7.1m (US$5.1m) for research into cardiovascular disease, especially into atherosclerosis - the commonest cause of death in Australia - to a team at Royal Prince Alfred Hospital and the Hanson Institute, South Australia. The funding, to be released over five years, is part of an Aus$10m initiative to boost research into age-related disease and care. Expressions of interest for the outstanding funds will be accepted until September 2 2005, through the National Health and Medical Research Council (NHMRC) from institutions registered with it. Further information at: www.nhmrc.gov.au
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.